Lercanidipine Hcl Viatris (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L-type calcium channels in vascular smooth muscle. By reducing calcium entry, it causes arterial vasodilation, which decreases peripheral vascular resistance and leads to a reduction in systemic blood pressure without markedly affecting heart contractility.

The dosage of Lercanidipine Hcl Viatris is individualized by the prescribing healthcare professional. The prescriber determines the appropriate strength and frequency based on the patient’s blood pressure response, age, renal and hepatic function, and any concomitant medications.

Safety of Lercanidipine in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will respond with pricing, availability, shipping details and any necessary import documentation.

Lercanidipine belongs to the dihydropyridine calcium‑channel blocker class, offering potent arterial vasodilation with a relatively low incidence of reflex tachycardia. Compared with agents such as amlodipine, Lercanidipine has a longer half‑life and may provide smoother blood‑pressure control, though clinical choice depends on individual patient factors and tolerability.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container to protect from moisture and light. Do not refrigerate or freeze the product, and keep it out of reach of children.

Lercanidipine Hcl Viatris is taken orally as a tablet. It can be swallowed with or without food, although taking it with a meal may reduce the risk of transient flushing. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

Serious adverse events, although rare, include severe hypotension, myocardial infarction, angioedema, hepatic dysfunction, and cardiac conduction disturbances such as heart block. Patients should seek immediate medical attention if they experience sudden dizziness, fainting, chest pain, swelling of the face or throat, or abnormal liver test results.

Lercanidipine is contraindicated in patients with known hypersensitivity to the drug or any component of the formulation, as well as in individuals with severe hypotension, cardiogenic shock, or unstable angina. Caution is also advised for patients with significant hepatic impairment or those taking strong CYP3A4 inhibitors.